44 results on '"A Mortier"'
Search Results
2. Hyperprogression in advanced melanoma is not restricted to immunotherapy
3. Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial
4. Efficacy, safety and factors associated with disease progression in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: An open label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib
5. Response to letter entitled: Hyperprogression in advanced melanoma is not restricted to immunotherapy
6. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial
7. Response to the letter: Hyperprogression in advanced melanoma is not restricted to immunotherapy
8. An open label, non-randomised, phase IIIb study of trametinib in combination with dabrafenib in patients with unresectable (stage III) or distant metastatic (stage IV) BRAF V600-mutant melanoma: A subgroup analysis of patients with brain metastases
9. BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
10. Photodynamic therapy for the treatment of primary cutaneous B-cell marginal zone lymphoma: a series of 4 patients
11. Efficiency of textile photodynamic therapy for mycosis fungoides
12. BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
13. Efficiency of textile photodynamic therapy for mycosis fungoides
14. Impact of expert pathology review in skin adnexal carcinoma diagnosis: Analysis of 2573 patients from the French CARADERM network
15. Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006
16. Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial
17. Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial
18. 17 (PB003) - BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC
19. Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort
20. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort
21. Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006
22. Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006
23. Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies
24. EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL)
25. Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006
26. EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL)
27. 3343 Exploratory analysis of vismodegib (VISMO) treatment discontinuation in the STEVIE study
28. 3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study
29. 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
30. 3343 Exploratory analysis of vismodegib (VISMO) treatment discontinuation in the STEVIE study
31. 3342 Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma (BCC) treated with vismodegib in the STEVIE study
32. 3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma
33. 1208 - Antitumor activity of ipilimumab after pembrolizumab in patients with advanced melanoma in KEYNOTE-006
34. 1207 - EURO-VOYAGE: Effectiveness and safety of ipilimumab (IPI) administered during a European Expanded Access Programme (EAP) in patients with advanced melanoma (MEL)
35. 1142 - Efficacy of pembrolizumab in patients with advanced mucosal melanoma enrolled in the KEYNOTE-001, 002, and 006 studies
36. 1141 - Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006
37. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)
38. P74 Evaluation of clinical response to neoadjuvant chemotherapy of large primary breast tumours (≥3.5 CM) and correlation with magnetic resonance imaging
39. Systemic treatment of metastatic malignant melanoma
40. P74 Evaluation of clinical response to neoadjuvant chemotherapy of large primary breast tumours (≥3.5 CM) and correlation with magnetic resonance imaging
41. Systemic treatment of metastatic malignant melanoma
42. Ther-PO-14 - Efficiency of textile photodynamic therapy for mycosis fungoides.
43. Tre-O2-07 - Lacutamab in patients (pts) with advanced mycosis fungoides (MF) according to KIR3DL2 expression: early results from the TELLOMAK phase 2 trial.
44. Ther-PO-15 - Photodynamic therapy for the treatment of primary cutaneous B-cell marginal zone lymphoma: a series of 4 patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.